Oric Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Oric Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($32.59M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($36.36M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($30.02M) | May 5, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($34.57M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($31.96M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($25.01M) | May 5, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($25.48M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($22.94M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($23.95M) | May 6, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($24.83M) | Nov 6, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($20.29M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($23.16M) | May 8, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($18.43M) | Nov 7, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($21.01M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($16.51M) | May 9, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($25.55M) | Nov 8, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($11.02M) | Aug 10, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($8.87M) | May 6, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($6.55M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($5.97M) | Aug 5, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($36.67M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($39.06M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($32.72M) | May 5, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($38.32M) | Nov 13, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($36.02M) | Aug 12, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($28.99M) | May 5, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($28.68M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($24.99M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($25.68M) | May 6, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($25.69M) | Nov 6, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($20.70M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($23.26M) | May 8, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($18.46M) | Nov 7, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($21.06M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($16.55M) | May 9, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($25.60M) | Nov 8, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($11.12M) | Aug 10, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($9.18M) | May 6, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($7.10M) | Nov 5, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($6.36M) | Aug 5, 2020 |